PRI report warns of risks tied to unauthorized GLP-1 knockoffs
A new Pacific Research Institute report warns that unauthorized compounded GLP-1 drugs may pose patient safety risks and hinder future pharmaceutical innovation.
PRI
A new Pacific Research Institute report warns that unauthorized compounded GLP-1 drugs may pose patient safety risks and hinder future pharmaceutical innovation.